1
Mohamed SKIBA Mohamed SKIBA
Skiba Mohamed, Skiba Malika, Bounoure Frédéric, Dechelotte Pierre: (Fr) Composition homogene et stable, riche en substances oleagineuses a base dun produit laitier, son procede de preparation et ses utilisations, (En) Homogeneous and stable composition rich in oleaginous substances based on a milk product, method for the preparation thereof and uses thereof. In Cyclo, Skiba Mohamed, Skiba Malika, Bounoure Frédéric, Dechelotte Pierre, BREDEMA, December 18, 2008: WO/2008/152226

(EN) The present invention relates to a stable and homogeneous milk composition based on milk comprising at least one cyclodextrin and at least one oleaginous substance. It also relates to the preparation thereof and also to products prepared therefrom, such as food compositions, powders, medicinal ...


2
Mohamed SKIBA Mohamed SKIBA
Skiba Mohamed, Skiba Malika, Bounoure Frederic, Dechelotte Pierre: Composition homogene et stable, riche en substances oleagineuses a base dun produit laitier, son procede de preparation et ses utilisations.. In Cyclo Soc Par Actions Simpl, November 14, 2008: FR2915901-A1

L'invention a pour objet une composition lactée stable et homogène à base de lait comprenant au moins une cyclodextrine et au moins une substance olagineuse. Elle concerne aussi sa préparation ainsi que des produits préparés à partir de celle-ci comme des compositions alimentaires, poudres, alicamen ...


3

4

5
James Doherty
Dorn Conrad P, Finke Paul E, Maccoss Malcolm, Doherty James B, Shah Shrenik K, Hagmann William K: New substituted azetidinones as anti-inflammatory and antidegenerative agents.. Merck & Co, April 22, 1992: EP0481671-A1 (40 worldwide citation)

New substituted azetidinones of the general formula (A') which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described. e


6
Eric First, M.D.
First Eric R, Irvine Ryan A: Methods for enhancing therapeutic effects of a neurotoxin. Allergan, First Eric R, Irvine Ryan A, NASSIF Claude, August 2, 2007: WO/2007/087154 (3 worldwide citation)

The present invention relates to methods for enhancing the therapeutic effects of a neurotoxin, e.g., a botulinum toxin, where the methods comprise a 'wash-down' (e.g., a decreased intake) of a current pain medication and an administration of a neurotoxin. In some embodiments, the present inventions ...


7
Stéphane De Lombaert
CHEN Zhidong, DE LOMBAERT Stéphane, DINES Jonathon Alan, LIU Weimin, LO Ho Yin, LOKE Pui Leng: INHIBITEURS BENZIMIDAZOLES DE LA PRODUCTION DE LEUCOTRIÈNES, BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION. BOEHRINGER INGELHEIM INTERNATIONAL, CHEN Zhidong, DE LOMBAERT Stéphane, DINES Jonathon Alan, LIU Weimin, LO Ho Yin, LOKE Pui Leng, MORRIS Michael P, May 3, 2012: WO/2012/058254

The present invention relates to compounds of formula IA and IB and pharmaceutically acceptable salts thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various disea ...


8
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Timothy M Caldwell, Bertrand L Chenard, Stéphane De Lombaert, Kevin J Hodgetts: Substituted quinolin-4-ylamine analogues. Neurogen Corporation, Edward Angell Palmer & Dodge, November 19, 2009: US20090286767-A1

Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion ...


9
Csaba Ékes
Istvan Vago, Gyula Beke, Eva Bozo, Sandor Farkas, Katalin Hornok, Gyorgy Keseru, Eva Schmidt, Eva Szentirmay, Monika Vastag: Benzamide derivatives as bradykinin antagonists. Richter Gedeon Nyrt, Fish & Richardson P C, July 9, 2013: US08481527

The present invention relates to new phenylsulfamoyl benzamide derivatives of formula (I) wherein R1-R5 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for prod ...


10
Vinayak Khairnar
Venkata P Palle, Sarala Balachandran, Nidhi Gupta, Vinayak Vasantrao Khairnar, Mandadapu Raghuramaiah, Abhijit Ray, Sunanda Ghose Dastidar: Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors. Ranbaxy Laboratories, March 29, 2011: US07915286

The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type IV selective inhibitors are provided. Prepared compounds correspond to ...